| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xuejiao Zhou, Xiaoning Zhang, Zhuzhu Wu, Xiaobo Xu, Ming Guo, Xin Zhai, Daiying Zuo, Yingliang W. The novel ALK inhibitor ZX-29 induces apoptosis through inhibiting ALK and inducing ROS-mediated endoplasmic reticulum stress in Karpas299 cells. Journal of biochemical and molecular toxicology. vol 35. issue 3. 2021-07-13. PMID:33140567. |
we demonstrated that zx-29 decreased karpas299 cells growth and had better cytotoxicity than ceritinib, which was mediated through downregulating the expression of alk and related proteins, inducing cell cycle arrest, and promoting cell apoptosis. |
2021-07-13 |
2023-08-13 |
Not clear |
| Xuejiao Zhou, Xiaoning Zhang, Zhuzhu Wu, Xiaobo Xu, Ming Guo, Xin Zhai, Daiying Zuo, Yingliang W. The novel ALK inhibitor ZX-29 induces apoptosis through inhibiting ALK and inducing ROS-mediated endoplasmic reticulum stress in Karpas299 cells. Journal of biochemical and molecular toxicology. vol 35. issue 3. 2021-07-13. PMID:33140567. |
taken together, zx-29 inhibited karpas299 cell proliferation and induced apoptosis through inhibiting alk and its downstream protein expression and inducing ros-mediated ers. |
2021-07-13 |
2023-08-13 |
Not clear |
| Hugo Larose, Nina Prokoph, Jamie D Matthews, Michaela Schlederer, Sandra Högler, Ali F Alsulami, Stephen P Ducray, Edem Nuglozeh, Feroze M S Fazaludeen, Ahmed Elmouna, Monica Ceccon, Luca Mologni, Carlo Gambacorti-Passerini, Gerald Hoefler, Cosimo Lobello, Sarka Pospisilova, Andrea Janikova, Wilhelm Woessmann, Christine Damm-Welk, Martin Zimmermann, Alina Federova, Andrea Malone, Owen Smith, Mariusz Wasik, Giorgio Inghirami, Laurence Lamant, Tom L Blundell, Wolfram Klapper, Olaf Merkel, Amos G A Burke, Shahid Mian, Ibraheem Ashankyty, Lukas Kenner, Suzanne D Turne. Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. vol 106. issue 6. 2021-07-07. PMID:32327503. |
moreover, inhibition of notch1 with γ-secretase inhibitors (gsis) or silencing by shrna leads to apoptosis; co-treatment in vitro with the alk inhibitor crizotinib led to additive/synergistic anti-tumour activity suggesting this may be an appropriate combination therapy for future use in the circumvention of alk inhibitor resistance. |
2021-07-07 |
2023-08-13 |
Not clear |
| Lijing Wang, Xiaobo Xu, Tong Liu, Junfang Wang, Jiwei Shen, Ming Guo, Yingliang Wu, Xin Zhai, Daiying Zu. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42), a novel ALK inhibitor, induces apoptosis and protective autophagy in H2228 cells. The Journal of pharmacy and pharmacology. vol 72. issue 10. 2021-06-22. PMID:32596809. |
1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (zx-42), a novel alk inhibitor, induces apoptosis and protective autophagy in h2228 cells. |
2021-06-22 |
2023-08-13 |
Not clear |
| Agnieszka Rybarczyk-Kasiuchnicz, Rodryg Ramlau, Katarzyna Stence. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. International journal of molecular sciences. vol 22. issue 2. 2021-03-29. PMID:33435596. |
the fusion of the two genes eml4 and alk results in a fusion gene that activates the intracellular signaling pathway, stimulates the proliferation of tumor cells, and inhibits apoptosis. |
2021-03-29 |
2023-08-13 |
Not clear |
| Shaodong Hong, Nan Chen, Wenfeng Fang, Jianhua Zhan, Qing Liu, Shiyang Kang, Xiaobo He, Lin Liu, Ting Zhou, Jiaxing Huang, Ying Chen, Tao Qin, Yaxiong Zhang, Yuxiang Ma, Yunpeng Yang, Yuanyuan Zhao, Yan Huang, Li Zhan. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology. vol 5. issue 3. 2021-01-12. PMID:27141355. |
cell apoptosis, viability and elisa test were used to study the immune suppression by alk activation and immune reactivation by alk-tkis and/or pd-1 blocking in tumor cells and dc-cik cells co-culture system. |
2021-01-12 |
2023-08-13 |
Not clear |
| Shaodong Hong, Nan Chen, Wenfeng Fang, Jianhua Zhan, Qing Liu, Shiyang Kang, Xiaobo He, Lin Liu, Ting Zhou, Jiaxing Huang, Ying Chen, Tao Qin, Yaxiong Zhang, Yuxiang Ma, Yunpeng Yang, Yuanyuan Zhao, Yan Huang, Li Zhan. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology. vol 5. issue 3. 2021-01-12. PMID:27141355. |
pd-l1 mediated by alk fusion protein increased the apoptosis of t cells in tumor cells and dc-cik cells co-culture system. |
2021-01-12 |
2023-08-13 |
Not clear |
| Wenfeng Gou, Zengqiang Li, Xiaobo Xu, Jiwei Shen, Ming Guo, Xuejiao Zhou, Xiaoning Zhang, Yingliang Wu, Xin Zhai, Daiying Zu. ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation. Biochimica et biophysica acta. Molecular cell research. vol 1867. issue 7. 2020-10-23. PMID:32224191. |
zx-29, a novel alk inhibitor, induces apoptosis via er stress in alk rearrangement nsclc cells and overcomes cell resistance caused by an alk mutation. |
2020-10-23 |
2023-08-13 |
mouse |
| Makoto Miyazaki, Ryo Otomo, Yuko Matsushima-Hibiya, Hidenobu Suzuki, Ayana Nakajima, Naomi Abe, Arata Tomiyama, Koichi Ichimura, Koichi Matsuda, Toshiki Watanabe, Takahiro Ochiya, Hitoshi Nakagama, Ryuichi Sakai, Masato Enar. The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas. Cell death discovery. vol 4. 2020-10-01. PMID:29760954. |
either alk inhibition or p53 activator treatment induced cell cycle arrest, whereas combination treatment induced apoptosis, and prevented tumour relapse both in vitro and in vivo. |
2020-10-01 |
2023-08-13 |
Not clear |
| Makoto Miyazaki, Ryo Otomo, Yuko Matsushima-Hibiya, Hidenobu Suzuki, Ayana Nakajima, Naomi Abe, Arata Tomiyama, Koichi Ichimura, Koichi Matsuda, Toshiki Watanabe, Takahiro Ochiya, Hitoshi Nakagama, Ryuichi Sakai, Masato Enar. The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas. Cell death discovery. vol 4. 2020-10-01. PMID:29760954. |
this shift toward apoptosis, and away from cell-cycle arrest, in the presence of an alk inhibitor and a p53 activator, is mediated by inhibition of the alk-akt-foxo3a axis leading to a specific upregulation of sox4. |
2020-10-01 |
2023-08-13 |
Not clear |
| Lian-Xiang Luo, Ying Li, Yu-Zhen Niu, Yu-Wei Wang, Qian-Qian Wang, Xing-Xing Fan, Jia-Hui Xu, Liang Liu, Elaine Lai-Han Leung, Xiao-Jun Ya. Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer. MedChemComm. vol 8. issue 10. 2020-09-30. PMID:30108712. |
herein, we identified the compound 5067-0952 as a potent alk inhibitor, which inhibited cell growth, induced apoptosis, and suppressed the phosphorylation of alk, subsequently blocking its downstream signaling pathway. |
2020-09-30 |
2023-08-13 |
Not clear |
| Lei Wang, Mingzhao Gao, Mengya Tong, Chengying Xie, Ye He, Li Fu, Yun Li, Haoyu Fu, Liguang Lo. Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met. American journal of cancer research. vol 8. issue 8. 2020-09-30. PMID:30210922. |
moreover, ct-711 profoundly inhibits alk signal transduction and thereby induces g1 phase arrest and apoptosis, and results in remarkable anti-proliferative activity against alk-driven cancer cells. |
2020-09-30 |
2023-08-13 |
mouse |
| Yuki Uchihara, Reiko Komori, Kenji Tago, Hiroomi Tamura, Megumi Funakoshi-Tag. Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells. Biochemical pharmacology. vol 170. 2020-07-01. PMID:31654627. |
methotrexate significantly induced apoptosis in alk inhibitor-resistant cells expressing the npm-alk mutant harboring the point mutation, g262r, and in alcl patient-derived npm-alk-positive ki-jk cells. |
2020-07-01 |
2023-08-13 |
Not clear |
| Marshall E Kadin, William P Adams, Giorgio Inghirami, Arianna Di Napol. Does Breast Implant-Associated ALCL Begin as a Lymphoproliferative Disorder? Plastic and reconstructive surgery. vol 145. issue 1. 2020-05-27. PMID:31577659. |
bia-alcl resembles cd30 cutaneous lymphoproliferative disorder: alk, cd30 anaplastic cells with an aberrant t-cell phenotype; overexpression of oncogenes (junb, satb1, pstat3, socs3) in lymphomatoid papulosis; frequent apoptosis; complete spontaneous regression in lymphomatoid papulosis; and partial spontaneous regression in cutaneous alcl. |
2020-05-27 |
2023-08-13 |
Not clear |
| Hao Yan, Jiangxia Du, Xueqin Chen, Bo Yang, Qiaojun He, Xiaochun Yang, Peihua Lu. ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicology and applied pharmacology. vol 383. 2020-05-20. PMID:31639374. |
importantly, crizotinib induced hepatocyte apoptosis independent of its targets, alk, ros1 and met. |
2020-05-20 |
2023-08-13 |
human |
| Muhammad Babar Jamshed, Fahad Munir, Numan Shahid, Ussama Sadiq, Syed Aun Muhammad, Noor Bader Ghanem, Hong Zhong, Xiaokun Li, Qiyu Zhan. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer. American journal of physiology. Gastrointestinal and liver physiology. vol 318. issue 1. 2020-05-04. PMID:31736340. |
overall, our research shows that ceritinib inhibits the alk signaling pathway, leading to cell growth/angiogenesis inhibition in pc and the induction of apoptosis. |
2020-05-04 |
2023-08-13 |
Not clear |
| Yulong Mao, Weiwei Zhang, Ronghe Zhang, Jinhua Zu. Alkannin restrains oral squamous carcinoma cell growth, migration and invasion by regulating microRNA-9/RECK axis. Artificial cells, nanomedicine, and biotechnology. vol 47. issue 1. 2019-12-24. PMID:31349748. |
then, brdu, flow cytometry, western blot and transwell assays were executed to appraise proliferation, apoptosis, migration and invasion in oscc cells with alk stimulation. |
2019-12-24 |
2023-08-13 |
Not clear |
| Zhen Yu, Ronglei Zha. Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma. Anti-cancer drugs. vol 29. issue 6. 2019-05-16. PMID:29570100. |
alk inhibitor exhibited antitumor effects by inhibiting alk activation, repressing akt and erk pathways, and suppressing antiapoptotic gene expressions, which subsequently promoted apoptosis and suppressed hcc cell proliferations. |
2019-05-16 |
2023-08-13 |
human |
| Hao Wu, Chao Zeng, Yiwang Ye, Jixian Liu, Zhimin Mu, Yuancai Xie, Baokun Chen, Qiaohong Nong, Da W. Exosomes from Irradiated Nonsmall Cell Lung Cancer Cells Reduced Sensitivity of Recipient Cells to Anaplastic Lymphoma Kinase Inhibitors. Molecular pharmaceutics. vol 15. issue 5. 2019-03-18. PMID:29595984. |
western blot, flow cytometry, mtt, and xenograft were employed to respectively assess activation of the alk pathway, apoptosis, cell viability, and tumor growth. |
2019-03-18 |
2023-08-13 |
mouse |
| Linlin Hu, Xiaonan Zhang, Jian Wang, Song Wang, Hesham M Amin, Ping Sh. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK Hematology (Amsterdam, Netherlands). vol 23. issue 5. 2018-10-15. PMID:29086626. |
involvement of oncogenic tyrosine kinase npm-alk in trifluoperazine-induced cell cycle arrest and apoptosis in alk trifluoperazine (tfp) has potential anticancer activity that was demonstrated in different types of cancer cells. |
2018-10-15 |
2023-08-13 |
Not clear |